November 10 is Neuroendocrine Cancer Awareness Day. As a company founded to bring a NET diagnostic to market, awareness of Neuroendocrine Cancer has been part of our mission from Day One. To this end, we join the NET community in creating awareness around this rare but rising disease.
In entering into a distribution agreement with Kindstar Globalgene Technology (Beijing, China), Wren Laboratories has expanded the global availability of our molecular neuroendocrine cancer diagnostic, the NETest. This partnership will double NETest utilization in 2024, providing oncologists for 300,000 NET cancer patients in China the ability to better understand their patient's tumor status and monitor therapy progression.
The NETest leverages both mRNA as its molecular foundation as well as Artificial Intelligence (AI) for gene assessment. introduced in 2014, the test has been utilized over 10,000 by oncologists and their patients to gain a better understanding of their Neuroendocrine Tumor activity and treatment progress.
Secretory tumor markers traditionally measured in patients with neuroendocrine tumors (NET) are lacking sensitivity and specificity, and consequently they are of limited clinical utility.
Analysis of ten studies indicates the NETest is an accurate (>95%) biomarker suitable for clinical use in NET disease management, exhibiting utility as an IVD to establish a diagnosis and monitor therapeutic efficacy.
The NETest is a standardized and reproducible liquid biopsy for neuroendocrine tumors (NETs). It evaluates the expression of 51 NET genes by real-time polymerase chain reaction, providing an accurate molecular profile of the neoplasm.
ASO Author Reflections: Circulating Neuroendocrine Gene Transcripts (NETest): A Promising Biomarker for Pancreatic Neuroendocrine Tumours (PanNET)
Recent research published in the Journal of Nuclear Medicine (April '23) has validated the role of the NETest as a predictor of the effectiveness of PRRT in treating NETs.
Surgical resection is the only effective curative strategy for small intestinal neuroendocrine neoplasms (SINENs). Nevertheless, the evaluation of residual disease and prediction of disease recurrence/progression remains a problematic issue.
The NETest PPQ–Peptide Receptor Radionuclide Therapy Predictor Quotient–exhibits over 97% accuracy in predicting positive response to PRRT for metastatic/inoperable NETs in real time.
Surgery is the only cure for neuroendocrine tumors (NETs), with R0 resection being critical for successful tumor removal. Early detection of residual disease is key for optimal management
The NETest, a multigene blood biomarker, is more accurate at predicting recurrence in NET resection surgery patients, providing greater efficiency for oncologists in managing neuroendocrine cancer treatment.
Blood-based genomic assessment is 90% accurate in predicting PRRT treatment response for NETs.
The NETest exhibited a 93% sensitivity and 89% specificity in identifying and differentiating lung malignancies including NSCLC from NETs.
This study demonstrates sensitivity and specificity benefits of a blood-based multianalyte NET gene transcript measurement to detect GI tract cancer.
NETest, a multigenomic mRNA biomarker exhibiting ~99% accuracy in NEN disease identification; is far more accurate than CgA (19–33%) and should be considered the biomarker standard of care.
NETest proves superior to CgA as effective marker for imaging, solid tumor grading, post surgery disease status and residual tumor detection.
Surgery significantly reduced NETest levels consistent with removal of the source of the circulating gene expression. In those with surgical cures (NED – no evidence of disease), elevated levels after surgery predicted disease recurrence.
Current biomarkers used in broncopulmonary neuroendocrine tumor management are single analytes and have a low utility, e.g., CgA (Chromogranin A) or NSE (neuron specific enolase). Blood NET gene levels accurately identified BPNETs (100%) and differentiated these from controls, benign and malignant lung disease.
A key issue in Gastroenteropancreatic neuroendocrine tumors (GEP-NETs) is early identification and prediction of disease progression. Clinical evaluation and imaging are limited due to the lack of sensitivity and disease indolence. We assessed the NETest as a predictive and prognostic marker of progression in a long-term follow-up...
NETest demonstrates a sensitivity of over 95% and a specificity of over 90% in detecting neuroendocrine cancer, making it four times more precise than CgA.
NETest is a highly accurate post-operative predictor of neuroendocrine tumor recurrence.
Noninvasive NETest-type diagnostics predict therapy success and provide therapy monitoring.
Wren Lab’s liquid biopsy has proven an effective biomarker for cancer treatment decision-making.
